Clinical Diagnostics and Research Tools
14 Mar 2022  |  North America
Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth
In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...
01 Mar 2022  |  Europe
Customer Experience Driven by New B2B and B2C Business Models
Diagnostics is the backbone of the healthcare sector. According to a World Health Organization (WHO) study, although the segment accounts for less than 5% of hospital costs, its findings influence 60–70% of healthcare decision-making. Diagnostics helps to analyze medical conditions and guide patients toward the right medication, treatment, or sur...
28 Feb 2022  |  North America
Advanced Molecular Diagnostics and At-Home Testing are Growth Prerequisites
The United States spends more than $3 trillion—nearly 18% of GDP—on healthcare, a massive sector. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population (16.9% in 2020); chronic disease burden; regulatory challenges; integration across the care continuum; migration to...
22 Feb 2022  |  North America
Non-invasive Liquid Biopsy Technology Shapes the Precision Diagnostics Landscape
Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...
24 Nov 2021  |  Global
Need for Scalable, Reproducible, and Cost-Effective Manufacturing Processes Driving Growth Opportunities
The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...
08 Oct 2021  |  North America
Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma
This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...
20 Sep 2021  |  North America
Personalized Diagnostics and Increased Healthcare Investment to Drive Market Growth Post COVID-19 Pandemic
The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...
12 Aug 2021  |  North America
A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines
Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...
30 Jun 2021  |  North America
Telegenetic Counseling to Revolutionize Access to Patient Care
In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...
26 Mar 2021  |  North America
An End-user Perspective on Laboratory Spending Reveals Modest 2021 Budget Increases Following Healthier 2020 Spending
Readers of one of Frost & Sullivanâ€™s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents yea...
Special Price $4,455.00 save 10 %